123 related articles for article (PubMed ID: 21275974)
1. Feasibility and efficacy of administration of bortezomib-containing regimens to patients over the age of 70 years.
Parrish C; Cromack J; Feyler S; Ashcroft J; Owen R; Cook G
Br J Haematol; 2011 Apr; 153(2):273-5. PubMed ID: 21275974
[No Abstract] [Full Text] [Related]
2. Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma.
Kamimura T; Miyamoto T; Takashima S; Yokota N; Chong Y; Ito Y; Akashi K
Int J Hematol; 2012 Oct; 96(4):525-7. PubMed ID: 22961216
[No Abstract] [Full Text] [Related]
3. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Rekhtman G; Masliak Z; Robak P; Esseltine DL; Feng H; Deraedt W; van de Velde H; Arnulf B
Haematologica; 2015 May; 100(5):e207-10. PubMed ID: 25596270
[No Abstract] [Full Text] [Related]
4. Cutaneous lesion induced by a subcutaneous administration of bortezomib.
Obeid KM; Ferrara R; Sharma M
Clin Lymphoma Myeloma Leuk; 2012 Aug; 12(4):284-6. PubMed ID: 22633164
[No Abstract] [Full Text] [Related]
5. Subcutaneous bortezomib: a step towards optimised drug use.
Mateos MV
Lancet Oncol; 2011 May; 12(5):410-1. PubMed ID: 21507716
[No Abstract] [Full Text] [Related]
6. Lupus tumidus induced by bortezomib not requiring discontinuation of the drug.
Aguayo-Leiva I; Vano-Galvan S; Carrillo-Gijon R; Jaén-Olasolo P
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1363-4. PubMed ID: 20337821
[No Abstract] [Full Text] [Related]
7. Bortezomib-related diffuse alveolar hemorrhage.
Wirk B
J Clin Oncol; 2012 Dec; 30(36):e379-81. PubMed ID: 23150703
[No Abstract] [Full Text] [Related]
8. An acceptable incidence of infusion site reactions after subcutaneous bortezomib administration in the upper arm in Japanese patients with multiple myeloma.
Ohgiya D; Tsuchiya T; Suyama T; Watanabe S; Numata H; Tsuboi K; Sasao T
Acta Haematol; 2015; 133(1):29-30. PubMed ID: 24993672
[No Abstract] [Full Text] [Related]
9. Bortezomib administration with severe hyperbilirubinemia caused by hepatic plasma cell infiltration: a case report.
Wilson N; Surati M; Walker BF; Kaufman JL; Harvey RD
Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):159-61. PubMed ID: 23084405
[No Abstract] [Full Text] [Related]
10. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.
Moreau P; Pylypenko H; Grosicki S; Karamanesht I; Leleu X; Grishunina M; Rekhtman G; Masliak Z; Robak T; Shubina A; Arnulf B; Kropff M; Cavet J; Esseltine DL; Feng H; Girgis S; van de Velde H; Deraedt W; Harousseau JL
Lancet Oncol; 2011 May; 12(5):431-40. PubMed ID: 21507715
[TBL] [Abstract][Full Text] [Related]
11. Bortezomib-induced skin eruption.
Sanchez-Politta S; Favet L; Kerl K; Dietrich PY; Piguet V
Dermatology; 2008; 216(2):156-8. PubMed ID: 18216478
[TBL] [Abstract][Full Text] [Related]
12. Adenovirus-associated hemorrhagic cystitis in a patient with plasma cell myeloma treated with bortezomib.
Yokose N; Hirakawa T; Inokuchi K
Leuk Res; 2009 Aug; 33(8):e106. PubMed ID: 19285724
[No Abstract] [Full Text] [Related]
13. Lymphocytopenia is associated with an increased risk of severe infections in patients with multiple myeloma treated with bortezomib-based regimens.
Jung SH; Bae SY; Ahn JS; Kang SJ; Yang DH; Kim YK; Kim HJ; Lee JJ
Int J Hematol; 2013 Mar; 97(3):382-7. PubMed ID: 23355264
[TBL] [Abstract][Full Text] [Related]
14. Re-transplantation after bortezomib-based therapy.
Morris C; Cook G; Streetly M; Kettle P; Drake M; Quinn M; Cavet J; Tighe J; Kazmi M; Ashcroft J; Cook M; Snowden J; Olujohungbe A; Marshall S; Conn J; Oakervee H; Popat R; Cavenagh J
Br J Haematol; 2011 Jun; 153(5):666-8. PubMed ID: 21275960
[No Abstract] [Full Text] [Related]
15. [Bortezomib-induced tumor lysis syndrome with a remarkable elevation of LDH in a case of relapsed and therapy-resistant multiple myeloma].
Arai A; Oshikawa G; Kurosu T; Miki T; Tohda S; Koyama T; Murakami N; Miura O
Rinsho Ketsueki; 2006 Aug; 47(8):777-80. PubMed ID: 16986718
[TBL] [Abstract][Full Text] [Related]
16. [Bortezomib-associated acute congestive heart failure in a patient with multiple myeloma].
Aota Y; Gotoh A; Hanyu N; Honma T; Morisaki M; Yokoyama T; Kitagawa N; Komatsu N
Rinsho Ketsueki; 2015 Jan; 56(1):44-7. PubMed ID: 25745969
[TBL] [Abstract][Full Text] [Related]
17. Bortezomib-induced perivascular dermatitis in a patient with multiple myeloma.
Ozkurt ZN; Sucak GT; Aki SZ; Yağci M; Erdem O
Cutan Ocul Toxicol; 2009; 28(3):141-3. PubMed ID: 19548772
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients.
Koh Y; Lee SY; Kim I; Kwon JH; Yoon SS; Park S; Chung MH; Suh SY; Kim KS; Kim HS
Cancer Chemother Pharmacol; 2014 Sep; 74(3):653-7. PubMed ID: 25096796
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib dosing in relapsed multiple myeloma.
Jagannath S
Clin Lymphoma Myeloma; 2006 Sep; 7(2):101-2. PubMed ID: 17026818
[No Abstract] [Full Text] [Related]
20. The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.
Jung JY; Kim HY; Han B; Choi DR; Zang DY; Kim HJ
Biomed Res Int; 2014; 2014():237698. PubMed ID: 24995276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]